PB2313: DARATUMUMAB AS A TREATMENT FOR ADULT IMMUNE THROMBOCYTOPENIA: A PHASE II STUDY WITH SAFETY RUN-IN (THE DART STUDY)

• G. Tsykunova,
• P. A. Holme,
• H. Thi Thyuet Tran,
• T. H. A. Tvedt,
• L. Munthe,
• M. Michel,
• H. Frederiksen,
• J. Bussel,
• D. Kuter,
• W. Ghanima

Affiliations

G. Tsykunova

1 Departments of Medicine, Hematology-Oncology, and Research, Østfold Hospital Trust, Kalnes

P. A. Holme

3 Institute of Clinical Medicine, University of Oslo

H. Thi Thyuet Tran

5 Department of Hematology, Akershus University Hospital

T. H. A. Tvedt

4 Department of Hematology, Oslo University Hospital

L. Munthe

6 K.G.Center for B-cell malignancies, Institute for Clinical Medicine,University of Oslo

M. Michel

8 Service de Médecine Interne 1, Centre de Référence des Cytopénies Auto-Immunes de l’Adulte, Centre Hospitalo-Universitaire Henri Mondor, Créteil, France

H. Frederiksen

9 Department of Hematology, Odense University Hospital, Odense, Denmark

J. Bussel

10 Department of Pediatrics, Weill Cornell Medicine, New York

D. Kuter

11 Division of Hematology, Massachusetts General Hospital,Harvard Medical School, Boston, United States of America

W. Ghanima

1 Departments of Medicine, Hematology-Oncology, and Research, Østfold Hospital Trust, Kalnes